The global iron drugs market is expected to register a CAGR of over 9%
during the period 2018-2022, according to the latest market research
report by Technavio.
This press release features multimedia. View the full release here:
Technavio has published a new market research report on the global iron drugs market from 2018-2022. (Graphic: Business Wire)
A key factor driving the market’s growth is the growing demand for
non-dextran IV iron drugs. Several IV iron complexes are available for
the treatment of iron deficiency anemia. Iron dextran is associated with
a high risk of anaphylactic reactions, whereas others must be
administered in numerous small infusions to avoid labile iron reactions.
The demand has shifted from conventional dextran IV iron drugs to
non-dextran IV iron drugs.
This market research report on the global
iron drugs market 2018-2022 provides an analysis of the
most important trends expected to impact the market outlook during the
forecast period. Technavio predicts an emerging trend as a major factor
that has the potential to significantly impact the market and contribute
to its growth or decline.
This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing
In this report, Technavio highlights the vendor focus on expanding the
reach of IV iron drugs as one of the key emerging trends in the global
iron drugs market:
Global iron drugs market: Vendor focus on
expanding the reach of IV iron drugs
Vendors are focusing on strategies to expand the reach and scope of IV
iron drugs. For instance, a major vendor is looking to consolidate its
presence in the market by expanding the reach of its flagship IV iron
drug. The number of units sold of the flagship IV iron drug increased
significantly across the world in 2015. This was because of the strong
demand in Australia, Germany, Spain, the Nordic countries, the UK, and
“Several companies are strengthening their position by conducting
disease awareness programs, clinical trials, and medical education
support for physicians. One of the research products is the study on
people with chronic heart failure and iron deficiency. Such initiatives
will increase the adoption of iron drugs in the forecast period,” says
a senior analyst at Technavio for research on infectious and rare
Global iron drugs market: Segmentation analysis
This market research report segments the global iron drugs market into
the following products (oral drug and IV drug) and key regions (the
Americas, APAC, and EMEA).
The oral drug segment held the largest market share in 2017, accounting
for more than 52% of the market. This product segment is expected to
dominate the global market throughout the forecast period.
The Americas held the highest share of the global iron drugs market in
2017, accounting for a market share of approximately 44%. This region is
anticipated to dominate the global market throughout the period
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Five Forces Analysis
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005381/en/